Latest News

Novartis launches COPD inhalers in China


NovartisNovartis (NYSE:NVS) has launched its Ultibro Breezhaler and Seebri Breezhaler in China for the treatment of chronic obstructive pulmonary disease.

The Ultibro Breezhaler system is a once-daily fixed-dose combination of indacaterol and glycopyrronium bromide. Seebri Breezhaler is a fixed-dose formulation of glycopyrronium bromide.

Get the full story at our sister site, Drug Delivery Business News.

The post Novartis launches COPD inhalers in China appeared first on MassDevice.

Source link

Related posts

Lassa fever kills 29 in Nigeria

Newsemia

New Sniper Balloon Occlusion Microcatheters Cleared in Europe

Newsemia

Essure System for Permanent Birth Control to Be Discontinued

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World